Joshua Richter, Madhav Dhodapkar, Mansi R. Shah, Joaquín Martinez-Lopez, Mina Awad, C. Akunna Otele, Mengying Li, Christian Hampp, Wenying Deng, Katherine Knorr, Tito Roccia, Glenn S. Kroog, Paula Rodríguez-Otero
{"title":"Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study","authors":"Joshua Richter, Madhav Dhodapkar, Mansi R. Shah, Joaquín Martinez-Lopez, Mina Awad, C. Akunna Otele, Mengying Li, Christian Hampp, Wenying Deng, Katherine Knorr, Tito Roccia, Glenn S. Kroog, Paula Rodríguez-Otero","doi":"10.1038/s41408-026-01636-2","DOIUrl":"https://doi.org/10.1038/s41408-026-01636-2","url":null,"abstract":"Patients with multiple myeloma are at increased risk of infection, highlighting the importance of evidence-based strategies for prevention, monitoring, and management of infections. In this post hoc analysis, we characterized infection events in 117 patients treated with linvoseltamab 200 mg in the Phase 1/2 LINKER-MM1 study (NCT03761108). Infection protection evolved during LINKER-MM1 in line with current guidelines to include mandated PJP prophylaxis and recommended antiviral prophylaxis and immunoglobulin replacement therapy (IgRT). At median follow-up of 14.3 months, infections were reported in 74.4% (Grade ≥ 3: 45.3%) of patients. The infection event rate (assessed in 3-month windows) during the first 6 months of treatment was 7.3–12.9 events/1000 patient-days (PD; Grade ≥ 3: 4.2–5.0/1000 PD), then declined and remained relatively stable after 6 months at 4.6–5.1/1000 PD (Grade ≥ 3: 0.5–1.0/1000 PD). The most common infection types during the first 6 months were coronavirus (any grade: 1.2–1.8/1000 PD; Grade ≥ 3: 0.6–0.9/1000 PD), upper respiratory tract (1.1–1.9/1000 PD; 0.0–0.1/1000 PD), and lower respiratory tract and lung infections (1.2–1.4/1000 PD; 1.0–1.0/1000 PD). Any grade infections resolved within a median (interquartile range) of 14.0 (8.0–29.0) days. A post hoc exploratory landmark analysis showed a trend towards lower risk of Grade ≥ 3 infections in patients receiving IgRT vs. those not having received IgRT during the first 3 months of follow-up (adjusted HR: 0.39 [95% CI: 0.11–1.32]). In summary, infection risk in patients treated with linvoseltamab notably decreases after 6 months of treatment and may be further mitigated by IgRT.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"19 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Doris K. Hansen, Brett M. Reid, Ariel Grajales-Cruz, Peter Cheng, Zhuoer Xie, Brandon Blue, Dae Hyun Lee, Laura Oswald, Gabriel De Avila, David Scheiber-Camoretti, Ken Harada, Daniel De Avila, Brandon Kale, Karla Feliciano Salva, David Kaldas, Kristy Matte, Todd Stinard, Rebecca Gonzalez, Victoria Alegria, Matthew Perciavalle, Helen Pai, Mukta Sharma, Kevin C. De Braganca, Zaina P. Qureshi, Fabiana Perna, Hien Liu, Kenneth H. Shain, Rachid Baz, Taiga Nishihori, Melissa Alsina, Ciara L. Freeman, Omar Alexis Castaneda Puglianini, Frederick L. Locke, Lauren C. Peres
{"title":"Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma","authors":"Doris K. Hansen, Brett M. Reid, Ariel Grajales-Cruz, Peter Cheng, Zhuoer Xie, Brandon Blue, Dae Hyun Lee, Laura Oswald, Gabriel De Avila, David Scheiber-Camoretti, Ken Harada, Daniel De Avila, Brandon Kale, Karla Feliciano Salva, David Kaldas, Kristy Matte, Todd Stinard, Rebecca Gonzalez, Victoria Alegria, Matthew Perciavalle, Helen Pai, Mukta Sharma, Kevin C. De Braganca, Zaina P. Qureshi, Fabiana Perna, Hien Liu, Kenneth H. Shain, Rachid Baz, Taiga Nishihori, Melissa Alsina, Ciara L. Freeman, Omar Alexis Castaneda Puglianini, Frederick L. Locke, Lauren C. Peres","doi":"10.1038/s41408-026-01633-5","DOIUrl":"https://doi.org/10.1038/s41408-026-01633-5","url":null,"abstract":"Ciltacabtagene autoleucel (cilta-cel) has demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). Bridging therapy (BT) is commonly used to mitigate progression pre-lymphodepletion (LD) and enhance safety and efficacy. However, real-world evidence characterizing BT strategies and outcomes is limited. This retrospective study included patients with RRMM who received commercial cilta-cel (May 2022–January 2025). Biochemical response to BT as well as post-infusion outcomes including cilta-cel response, progression-free survival (PFS), and safety were assessed. Among 192 patients receiving cilta-cel, 172 (90%) received BT. Of 115 patients with evaluable biochemical response to BT, 54% achieved decreased disease, with response highest among talquetamab and proteasome inhibitor-based regimens. Safety was consistent with the known cilta-cel profile. Reduction in disease burden during BT was associated with lower rates of grade ≥ 3 ICANS, while alkylator-based BT had higher rates of grade ≥ 3 cytopenias. Overall response rate to cilta-cel was 92% (69% with at least complete response), with numerically higher rates among those with decreased disease during BT. Median PFS was not reached among patients with decreased disease during BT versus 16.2 months among those with stable/increased disease (p = 0.03). Findings suggest that biochemical response to BT may enhance the benefit-risk profile of cilta-cel in clinical practice.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"4 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Steven M. Kornblau, Eduardo Sabino de Camargo Magalhães, Brandon D. Brown, Samanta Soledad Catueno, Yihua Qiu, Eitan Kugler, Abhishek Maiti, Warren C. Fiskus, Tapan Kadia
{"title":"High MECOM protein levels confer adverse prognosis in acute myeloid leukemia independent of Chromosome 3 abnormalities","authors":"Steven M. Kornblau, Eduardo Sabino de Camargo Magalhães, Brandon D. Brown, Samanta Soledad Catueno, Yihua Qiu, Eitan Kugler, Abhishek Maiti, Warren C. Fiskus, Tapan Kadia","doi":"10.1038/s41408-026-01629-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01629-1","url":null,"abstract":"MDS1 and EVI1 Complex locus (MECOM) gene rearrangements (MECOM-R) occur in ~2% of AML, with EVI1 protein overexpression causing aggressive disease. EVI1 overexpression in non-MECOM-R cases also occurs and is prognostically adverse, suggesting that EVI1 protein overexpression could induce similar biological programs without MECOM-R. We measured MECOM protein in 810 untreated AML cases (MECOM-R = 2%), observing low protein in 86% and high expression in 14%. High protein was equally prognostically adverse with MECOM-R, other Chromosome 3 (Chr3) abnormalities (Chr3-abn), or Chr3-wild-type (WT). Despite high protein expression co-associating with known adverse features, high MECOM was independently prognostic in CoxPH models. High MECOM protein overrides the benefit of mutant CEBPα protein. Protein-protein correlations and networks were similar between MECOM-R, Chr3-WT-high and Chr3-abn-High, with common activated pathways, but also distinct ones. Chr3-WT-high cases also overexpressed MDS1/EVI1 and expressed proteins favoring epigenetic deregulation, explaining some observed differences. Collectively, we showed that elevated MECOM protein levels in non-MECOM-R cases are equally adverse to MECOM-R cases, and share similar biological programs, suggesting that therapies targeting MECOM-related proteins may be efficacious beyond those with MECOM-R. Clinically measuring MECOM protein levels could be a useful strategy to stratify patients and guide therapy recommendations.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"18 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon
{"title":"Redefining the role of second transplantation in adult ALL with post-transplant relapse in the modern era of immuno-targeted therapies.","authors":"Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon","doi":"10.1038/s41408-026-01628-2","DOIUrl":"https://doi.org/10.1038/s41408-026-01628-2","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B Alkhateeb, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A Elliott, Mark R Litzow, William J Hogan, Mithun V Shah, Mrinal M Patnaik, Animesh Pardanani, Dong Chen, Kaaren K Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H Begna
{"title":"Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia.","authors":"Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B Alkhateeb, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A Elliott, Mark R Litzow, William J Hogan, Mithun V Shah, Mrinal M Patnaik, Animesh Pardanani, Dong Chen, Kaaren K Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H Begna","doi":"10.1038/s41408-026-01615-7","DOIUrl":"10.1038/s41408-026-01615-7","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexis Claudel, Pierre-Julien Viailly, Pierre Feugier, Cedric Rossi, Jessie Bourcier, Francois Lemonnier, Vincent Camus, Vincent Ribrag, Eric Durot, Gian Matteo Pica, Emmanuelle Nicolas-Virelizier, Benoit Tessoulin, Emmanuel Bachy, Stephanie Guidez, Nicolas Daguindau, Clementine Sarkozy, Luc Xerri, Cedric Portugues, Nesrine Trabelsi, Franck Morschhauser, Marie-Helene Delfau-Larue
{"title":"End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial","authors":"Alexis Claudel, Pierre-Julien Viailly, Pierre Feugier, Cedric Rossi, Jessie Bourcier, Francois Lemonnier, Vincent Camus, Vincent Ribrag, Eric Durot, Gian Matteo Pica, Emmanuelle Nicolas-Virelizier, Benoit Tessoulin, Emmanuel Bachy, Stephanie Guidez, Nicolas Daguindau, Clementine Sarkozy, Luc Xerri, Cedric Portugues, Nesrine Trabelsi, Franck Morschhauser, Marie-Helene Delfau-Larue","doi":"10.1038/s41408-026-01631-7","DOIUrl":"https://doi.org/10.1038/s41408-026-01631-7","url":null,"abstract":"In this ancillary study of the RELEVANCE phase III trial (NCT01650701), we performed the first direct intra-patient comparison of circulating tumor DNA (ctDNA)-based versus cellular t(BCL2/JH) translocation-based MRD at end of induction (EOI) in 278 patients with advanced FL, for the prediction of progression within 24 months (POD24). Conventional cellular t(BCL2/JH) MRD in peripheral blood (PB) and/or bone marrow (BM) had been previously assessed by digital PCR across MBR, 3’MBR, and mcr breakpoint regions; ctDNA was assessed by targeted NGS of phased variants in cell-free DNA (cfDNA) using a custom 111-gene, 130-kb panel. Trackable phased variants were identified at baseline in 242/278 patients (87%) for cfDNA, versus 145/278 (52%) for PB/BM t(BCL2/JH) (p < 0.001). Among 132 patients informative for both markers, ctDNA-based MRD at EOI predicted PFS more strongly (HR 4.5, 95% CI 2.2–9.1) than t(BCL2/JH)-based MRD (HR 2.9, 95% CI 1.5–5.6), and had a higher positive predictive value for POD24 (50.0% vs 14.3%, p = 0.009) with a numerically higher negative predictive value (94.1% vs 90.1%, p = 0.051). EOI ctDNA positivity was the only MRD marker associated with inferior OS in an exploratory univariate analysis (9 events; HR 5.6, 95% CI 1.3–23.3; log-rank p = 0.008). These data establish ctDNA-based MRD as a more broadly applicable and clinically actionable POD24 predictor than t(BCL2/JH)-based MRD in first-line advanced FL.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"23 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joseph S. Hong, Lingxiao Zhang, Baijun Zhou, Katherine J. Liu, Andrew J. Yee, Sara Barmettler
{"title":"Hypogammaglobulinemia, neutropenia, and lymphopenia, and risk for infection and mortality in patients following daratumumab for multiple myeloma","authors":"Joseph S. Hong, Lingxiao Zhang, Baijun Zhou, Katherine J. Liu, Andrew J. Yee, Sara Barmettler","doi":"10.1038/s41408-026-01626-4","DOIUrl":"https://doi.org/10.1038/s41408-026-01626-4","url":null,"abstract":"Daratumumab is an IgG kappa monoclonal antibody targeting CD38 approved for the treatment of multiple myeloma. While lymphopenia and neutropenia have been described, the broader immunologic impact, including hypogammaglobulinemia (IgG ≤600 mg/dL), remains undercharacterized. We performed a retrospective analysis of 614 adults receiving daratumumab for multiple myeloma; evaluating demographics, disease characteristics, hypogammaglobulinemia, lymphopenia, neutropenia, infections, immunoglobulin replacement (IVIG) use, and mortality. Mean IgG levels decreased from 568 mg/dL to 371 mg/dL following daratumumab, and hypogammaglobulinemia prevalence rose from 64.3% to 87.9%, with increasing severity. Lymphopenia and neutropenia prevalence and severity also increased. Hypogammaglobulinemia pre-daratumumab was associated with increased risk for infection (IRR 1.28, 95% CI 1.08–1.51), with severe hypogammaglobulinemia conferring the highest risk (IRR 1.85, 95% CI 1.45–2.35). Lower IgG levels were associated with infection risk. Baseline hypogammaglobulinemia, lymphopenia, and neutropenia were associated with increased mortality. When IVIG exposure was modeled as a time-varying variable, infection risk was significantly higher during periods off of IVIG compared with on IVIG (IRR 2.43, 95% CI 1.70–3.48). These findings support closer monitoring of IgG, ALC, and ANC beginning prior to daratumumab initiation and continued at regular intervals, with earlier consideration of immunoglobulin replacement in patients with hypogammaglobulinemia and infectious complications.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul J. Hampel,Ying Huang,John N. Allan,Seema A. Bhat,David Bond,Danielle M. Brander,John C. Byrd,Julio C. Chavez,Elise Chong,Alexey Danilov,Matthew S. Davids,Kaitlyn Dvorak-Kornaus,Hannah Freedman,Nikita Malakhov,Matthew Matasar,Cecelia Miller,Sarah Miller,Zulfa Omer,Sameer A. Parikh,Erin M. Parry,Kari G. Rabe,Phil Raess,Manoj Rai,Joanna M. Rhodes,Kerry A. Rogers,Aditi Saha,Jake Schade,Geoffrey Shouse,Stephen Spurgeon,Deborah Stephens,Yucai Wang,Jennifer A. Woyach,Max Yano,Adam S. Kittai
{"title":"Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia","authors":"Paul J. Hampel,Ying Huang,John N. Allan,Seema A. Bhat,David Bond,Danielle M. Brander,John C. Byrd,Julio C. Chavez,Elise Chong,Alexey Danilov,Matthew S. Davids,Kaitlyn Dvorak-Kornaus,Hannah Freedman,Nikita Malakhov,Matthew Matasar,Cecelia Miller,Sarah Miller,Zulfa Omer,Sameer A. Parikh,Erin M. Parry,Kari G. Rabe,Phil Raess,Manoj Rai,Joanna M. Rhodes,Kerry A. Rogers,Aditi Saha,Jake Schade,Geoffrey Shouse,Stephen Spurgeon,Deborah Stephens,Yucai Wang,Jennifer A. Woyach,Max Yano,Adam S. Kittai","doi":"10.1038/s41408-026-01622-8","DOIUrl":"https://doi.org/10.1038/s41408-026-01622-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"5 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oren Pasvolsky,Bruno Almeida Costa,Yosra M. Aljawai,Krina K. Patel,Qaiser Bashir,Dawen Sui,Samer A. Srour,Mark R. Tanner,Uday R. Popat,Neeraj Y. Saini,Chitra Hosing,Jeremy L. Ramdial,Hans C. Lee,Gregory P. Kaufman,Sheeba K. Thomas,Donna M. Weber,Melody Becnel,Guilin Tang,Robert Z. Orlowski,Richard E. Champlin,Yago Nieto,Elizabeth J. Shpall,Muzaffar H. Qazilbash
{"title":"Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study","authors":"Oren Pasvolsky,Bruno Almeida Costa,Yosra M. Aljawai,Krina K. Patel,Qaiser Bashir,Dawen Sui,Samer A. Srour,Mark R. Tanner,Uday R. Popat,Neeraj Y. Saini,Chitra Hosing,Jeremy L. Ramdial,Hans C. Lee,Gregory P. Kaufman,Sheeba K. Thomas,Donna M. Weber,Melody Becnel,Guilin Tang,Robert Z. Orlowski,Richard E. Champlin,Yago Nieto,Elizabeth J. Shpall,Muzaffar H. Qazilbash","doi":"10.1038/s41408-026-01620-w","DOIUrl":"https://doi.org/10.1038/s41408-026-01620-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"31 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
